163 related articles for article (PubMed ID: 27252563)
1. Barriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014.
King A; Bornschlegel K; Johnson N; Rude E; Laraque F
Public Health Rep; 2016; 131(3):430-7. PubMed ID: 27252563
[TBL] [Abstract][Full Text] [Related]
2. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.
Behrends CN; Gutkind S; Deming R; Fluegge KR; Bresnahan MP; Schackman BR
J Urban Health; 2021 Aug; 98(4):563-569. PubMed ID: 32016914
[TBL] [Abstract][Full Text] [Related]
3. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.
Sherbuk JE; Tabackman A; McManus KA; Kemp Knick T; Schexnayder J; Flickinger TE; Dillingham R
Harm Reduct J; 2020 Sep; 17(1):64. PubMed ID: 32948189
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City.
Moore MS; Bocour A; Jordan L; McGibbon E; Varma JK; Winters A; Laraque F
J Public Health Manag Pract; 2018; 24(6):526-532. PubMed ID: 29227418
[TBL] [Abstract][Full Text] [Related]
5. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
6. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
7. Perceptions of drug users regarding hepatitis C screening and care: a qualitative study.
Jordan AE; Masson CL; Mateu-Gelabert P; McKnight C; Pepper N; Bouche K; Guzman L; Kletter E; Seewald RM; Des-Jarlais DC; Sorensen JL; Perlman DC
Harm Reduct J; 2013 Jun; 10():10. PubMed ID: 23786800
[TBL] [Abstract][Full Text] [Related]
8. Enhanced chronic hepatitis C surveillance in New York City, April 2009-January 2011.
Drezner K; Bornschlegel K; McGibbon E; Balter S
Public Health Rep; 2013; 128(6):510-8. PubMed ID: 24179262
[TBL] [Abstract][Full Text] [Related]
9. Family medicine-directed hepatitis C care and barriers to treatment: a mixed-methods study.
von Aesch Z; Craig-Neil A; Shah H; Antoniou T; Meaney C; Pinto AD
CMAJ Open; 2021; 9(1):E201-E207. PubMed ID: 33688028
[TBL] [Abstract][Full Text] [Related]
10. A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.
Behrends CN; Eggman AA; Gutkind S; Bresnahan MP; Fluegge K; Laraque F; Litwin AH; Meissner P; Shukla SJ; Perumalswami PV; Weiss J; Wyatt BE; Schackman BR
J Public Health Manag Pract; 2019; 25(3):253-261. PubMed ID: 29975342
[TBL] [Abstract][Full Text] [Related]
11. Offers of hepatitis C care do not lead to treatment.
Schackman BR; Teixeira PA; Beeder AB
J Urban Health; 2007 May; 84(3):455-8. PubMed ID: 17394085
[TBL] [Abstract][Full Text] [Related]
12. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders.
Appel PW; Ellison AA; Jansky HK; Oldak R
Am J Drug Alcohol Abuse; 2004; 30(1):129-53. PubMed ID: 15083558
[TBL] [Abstract][Full Text] [Related]
13. Estimating the prevalence of chronic hepatitis C virus infection in New York City, 2015.
Bocour A; Greene SK; Laraque F; Winters A
Epidemiol Infect; 2018 Sep; 146(12):1537-1542. PubMed ID: 29932040
[TBL] [Abstract][Full Text] [Related]
14. A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017.
Moore MS; Bocour A; Laraque F; Winters A
Public Health Rep; 2018; 133(4):497-501. PubMed ID: 29902392
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C infection among men who have sex with men living with HIV in New York City, 2000-2015.
Gabai CM; Moore MS; Penrose K; Braunstein S; Bocour A; Neaigus A; Winters A
Sex Transm Infect; 2020 Sep; 96(6):445-450. PubMed ID: 31801894
[TBL] [Abstract][Full Text] [Related]
16. An Evaluation of Hepatitis C Virus Telehealth Services Serving Tribal Communities: Patterns of Usage, Evolving Needs, and Barriers.
Stephens D; Leston J; Terrault NA; Gailloux K; Mera J; Essex W; Reilley B
J Public Health Manag Pract; 2019; 25 Suppl 5, Tribal Epidemiology Centers: Advancing Public Health in Indian Country for Over 20 Years():S97-S100. PubMed ID: 31348196
[TBL] [Abstract][Full Text] [Related]
17. Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017.
Webster R; Moore MS; Bocour A; Johnson N; Winters A
Public Health Rep; 2020; 135(6):823-830. PubMed ID: 32886566
[TBL] [Abstract][Full Text] [Related]
18. Association Between Time to First RNA-Negative Test Result Among People With Hepatitis C Virus Infection and Homelessness or Testing at a Correctional or Substance Use Treatment Facility, New York City.
Moore MS; Bocour A
Public Health Rep; 2022; 137(6):1126-1135. PubMed ID: 34694921
[TBL] [Abstract][Full Text] [Related]
19. Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City.
Guerra K; Bocour A; Moore MS; Winters A
J Public Health Manag Pract; 2022 Mar-Apr 01; 28(2):126-129. PubMed ID: 32956285
[TBL] [Abstract][Full Text] [Related]
20. "Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City.
Kapadia SN; Aponte-Melendez Y; Rodriguez A; Pai M; Eckhardt BJ; Marks KM; Fong C; Mateu-Gelabert P
Harm Reduct J; 2023 Jul; 20(1):95. PubMed ID: 37501180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
